期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤坏死因子拮抗剂防治脓毒症的研究现状 被引量：1

An update review:tumour necrosis factor as a therapeutic target in sepsis
下载PDF
导出
摘要 内毒素诱生多种介质的参与是脓毒症发病的重要环节，其中肿瘤坏死因子－α（ＴＮＦ－α）可能在内毒素诱发的炎症介质“瀑布效应”中起重要作用。本文针对ＴＮＦ－α合成的５个作用环节，概述了ＴＮＦ－α拮抗剂防治脓毒症的研究现状。 Tumour necrosis factor (TNF) is an essential mediator in the pathogenesis of septic shock associated with lipopolysaccharide (LPS) from gram negative organisms. For these reasons, there was considerable expectation that modulation of the TNF response would be of benefit to patients suffering the consequences of severe infection. In this review, the treatment approach in TNF mediated sepsis will be considered at five steps in the TNF biosynthetic pathway.
作者 方文慧 姚咏明 盛志勇
机构地区 解放军
出处 《创伤外科杂志》 2001年第2期152-154,共3页 Journal of Traumatic Surgery
关键词 肿瘤坏死因子-Α 脓毒症 治疗 肿瘤坏死因子拮抗剂 tumour necrosis factor-α sepsis therapy
分类号 R631.2 [医药卫生—外科学]
  • 相关文献

参考文献11

  • 1[1]Lauterbach R, Pawlik D, Kowalczyk D, et al. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial[J].Crit Care Med,1999,27(4):807-814.
  • 2[2]Parker SJ, Brown D, Kenward CE, et al. Pentoxifylline fails to improve organ dysfunction and survival when used in the resuscitation of a porcine model of haemorrhage and abdominal sepsis[J]. Resuscitation,2000,44(1):61-69.
  • 3[3]Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group[J]. Crit Care Med, 1996,24(9):1431-1440.
  • 4[4]Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock[J]. NORASEPT II Study Group [see comments]Lancet, 1998,351(9107):929-933.
  • 5[5]Feldmann M, Bondeson J, Brennan FM, et al. The rationale for the current boom in anti-TNF alpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNF alpha and minimise hazards[J]? Ann Rheum Dis, 1999,58(Suppl 1):127-131.
  • 6[6]Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group [see comments][J].N Engl J Med, 1996,334(26):1697-1702.
  • 7[7]Abraham E, Glauser MP, Butler T, et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group[J]. JAMA, 1997,277(19):1531-1538.
  • 8[8]Pittet D, Harbarth S, Suter PM, et al. Impact of immunomodulating therapy on morbidity in patients with severe sepsis[J]. Am J Respir Crit Care Med, 1999,160(3):852-857.
  • 9[9]Acton RD, Dahlberg PS, Uknis ME, et al. Differential sensitivity to escherichia coli infection in mice lacking tumor necrosis factor p55 or interleukin-1 p80 receptors[J]. Arch Surg, 1996,131(11):1216-1221.
  • 10[10]Schultze RL, Gangopadhyay A, Cay O, et al. Tyrosine kinase activation in LPS stimulated rat Kupffer cells[J]. Cell Biochem Biophys, 1999,30(2):287-301.

同被引文献25

  • 1[1]Shalaby M R,Palladino M A.An overview of the history and biological properties of tumour necrosis factors.Springe Semin Immun,1996,9(1):33～37
  • 2[2]Bazzoni F,Beutler B.How do tumour necrosis factor receptors work? J Immfla,1995,45:221～238
  • 3[3]Engelman H,Novick D,Wallach D,et al.Two tumour necrosis factor-binding protein purified from human urine.J Biol Chem,1990,265:1531～1536
  • 4[4]Aderka D,Engeimann H,Mar Y,et al.Stabilization of the bioactivity of tumour necrosis by its soluble receptors TNFs.J Exp Med,1992,175:323
  • 5[5]Jones E K,Stuort D I,Welker N P,et al.Structure of tumout necrosis factor.Nature,1989,338:225～228
  • 6[7]Adrie C,Pinsky M R.The inflammatory balance in human sepsis.Intens Care Med 2000,26:364～375
  • 7[8]Karima R,Matsumoto S,Higashi H,et al.The molecular pathogenesis of Endotoxic shock and organ failure.Mol Med Today,1999,5:123～132
  • 8[9]Stahel P F,Barnum S R.Bacterial meningitis:complement gene expression in the central nervous system.Immunopharmacology,1997,38:65～72
  • 9[10]Gonzalez A R,Garcia M C,Garcia B L,et al.Induction of tumour necrosis factor α production by human hepatocytes in chronic viral hepatitis.J Exp Mad,1994,179(2):841～848
  • 10[11]Weiner F R,Shah A,Smith P J,et al.Regulation of collagen gene experession in 3t3-L1 cells.Effects of adipocyte differentiation and tumor necrosis factor-α.Biochemistry,1989,28:4094～4099

引证文献1

二级引证文献4

创伤外科杂志
2001年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部